Form 4 for NAGE Niagen Bioscience, Inc.
Accepted 2026-07-08 17:17:37 ET · period of report 2026-06-30 · accession 0001834681-26-000001 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-08 17:17 | 2026-06-30 | NAGE | Pamir Ozan | CFO | A - Grant | $2.71 | +4,255 | 11.6K | +58% | +$11.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-30 | A | A | 4,255 | $2.71 | 11,627.16 | D | — | — | (F1) Shares acquired pursuant to the Issuer's Employee Stock Purchase Plan. The acquisition is exempt under Rule 16b-3(c) and 16b-3(d). |